The Effect of Ras Homolog C/Rho-Associated Coiled-Protein Kinase (Rho/ROCK) Signaling Pathways on Proliferation and Apoptosis of Human Myeloma Cells.

The Effect of Ras Homolog C/Rho-Associated Coiled-Protein Kinase (Rho/ROCK) Signaling Pathways on Proliferation and Apoptosis of Human Myeloma Cells. Med Sci Monit. 2019 Oct 10;25:7605-7616 Authors: Feng X, Zhang L, Nie S, Zhuang L, Wang W, Huang J, Yan X, Meng F Abstract BACKGROUND The aim of this study was to explore the impact of Ras homolog C/Rho-associated coiled-protein kinase (Rho/ROCK) signaling pathways intervention on biological characteristics of the human multiple myeloma cell lines RPMI-8226 and U266 cells, and to investigate the expression of RhoC, ROCK1, and ROCK2 in RPMI-8226 and U266 cells. MATERIAL AND METHODS RPMI8226 and U266 cell lines were treated by 5-aza-2-deoxycytidine (5-Aza-Dc), trichostatin A (TSA), RhoA inhibitor CCG-1423, Rac1 inhibitor NSC23766, and ROCK inhibitor fasudil. Cell proliferation was examined by Cell Counting Kit-8 (CCK-8) assay and clone formation. Cell apoptosis was examined by flow cytometry and TUNEL assay. The mRNA and protein expressions of RhoC, ROCK1, and ROCK2 were detected by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blot, respectively. RESULTS CCG-1423, NSC23766, and fasudil could significantly inhibit the proliferation of RPMI8226 and U266 cells. The inhibitory effect was dose- and time-dependent within a certain concentration range (P
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research

Related Links:

Condition:   Multiple Myeloma Interventions:   Drug: Hydroxychloroquine;   Drug: Carfilzomib Injection;   Drug: Dexamethasone Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital;   Oslo University Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Relapsed And-or Refractory Multiple Myeloma and Plasmacytoid Lymphoma Intervention:   Biological: BCMA-CD19 cCAR T cells Sponsors:   iCell Gene Therapeutics;   iCAR Bio, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Relapsed/Refractory, High Risk Multiple Myeloma Intervention:   Biological: CD4 CAR T cells Sponsors:   iCell Gene Therapeutics;   iCAR Bio, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Myeloma Interventions:   Drug: Belantamab mafodotin;   Drug: Pom/dex (Pomalidomide plus low dose Dexamethasone) Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Myeloma Intervention:   Biological: BCMA-PD1-CART Cell Sponsor:   Chinese PLA General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionNEAT1 promoted M2 macrophage polarization by sponging miR-214 and then regulating B7-H3, thus accelerating MM progression via the JAK2/STAT3 signaling pathway. Our study revealed novel mechanisms of M2 macrophage polarization and provided new potential clinical therapeutic targets for MM.
Source: Molecular Immunology - Category: Allergy & Immunology Source Type: research
ConclusionsThese data demonstrate that a transplantation protocol involving only selective tumor-reactive donor T cell families is an effective immunotherapy and results in long-term survival in a mouse model of human MM. The results highlight the need to develop similar ATCT strategies for MM patients that result in enhanced survival without symptoms of GvHD.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
In our multiple myeloma quiz, you'll get a chance to test your knowledge on best practices to implement shared decision-making when discussing treatment options with your patients.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Publication date: Available online 11 November 2019Source: Blood Cells, Molecules, and DiseasesAuthor(s): Jana Volejnikova, Petr Vojta, Helena Urbankova, Renata Mojzíkova, Monika Horvathova, Ivana Hochova, Jaroslav Cermak, Jan Blatny, Martina Sukova, Eva Bubanska, Jaroslava Feketeova, Daniela Prochazkova, Julia Horakova, Marian Hajduch, Dagmar PospisilovaAbstractDiamond-Blackfan anemia (DBA) is a rare congenital erythroid aplasia, underlied by haploinsufficient mutations in genes coding for ribosomal proteins (RP) in approximately 70% of cases. DBA is frequently associated with somatic malformations, endocrine dysfu...
Source: Blood Cells, Molecules, and Diseases - Category: Hematology Source Type: research
AbstractBackground.The prognostic value of 1q21 gain in newly diagnosed multiple myeloma (NDMM) remains controversial. Our aim was to investigate the prognostic value of 1q21 gain in a Chinese population.Materials and Methods.We retrospectively identified 565 patients with NDMM from multiple centers in China.Results.We detected 1q21 gain in 222 (39.3%) patients, among whom 144 had three copies of 1q21, 57 had four copies of 1q21, and 21 had at least five copies of 1q21. Copy number variation did not show any effect on the disease outcome. Multivariate analysis indicated that 1q21 gain was an independent factor for poor pro...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Myelomas, Hematologic Malignancies Source Type: research
More News: Biomedical Science | Men | Myeloma | Research | Science | Study